Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders

A method of reducing or attenuating the biological activity of secreted adipocyte protein 2 (aP2) in a human comprising administering an effective amount of a humanized anti-aP2 monoclonal antibody or antigen binding agent comprising:

• (a) a light chain variable region comprising:
• (i) a CDR-L1 complementarity determining region (CDR) comprising the amino acid sequence of Seq. ID No. 7;
• (ii) a CDR-L2 CDR comprising the amino acid sequence of Seq. ID No. 8;
• and
• (iii) a CDR-L3 CDR comprising an amino acid sequence selected from the group consisting of Seq. ID No. 9, Seq. ID No. 10, Seq. ID No. 11, and Seq. ID No. 12;
• and
• (b) a heavy chain variable region comprising:
• a CDR-H1 CDR comprising the amino acid sequence of Seq. ID No.14;
• (ii) a CDR-H2 CDR comprising an amino acid sequence selected from the group consisting of Seq. ID No. 16 and Seq. ID No. 17;
• and
• (iii) a CDR-H3 CDR comprising an amino acid sequence selected from the group consisting of Seq. ID No. 19 and Seq. ID No. 20.